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Diabetes management before and after cancer diagnosis: missed
opportunity
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Background: Few studies have examined the management of comorbidities in cancer patients. This study used
population-based data to estimate the guideline concordance rates for diabetes management before and after cancer
diagnosis and examined if diabetes management services among cancer patients was associated with characteristics
of the hospital where the patient was treated.

Methods: We linked 2005-2009 Medicare claims data to information on 2,707 breast and colorectal cancers
patients in state cancer registry files. Multivariate logistic regression models examined hospital characteristics
associated with receipt of diabetes management care after cancer diagnosis.

Results: The rates of HbAlc testing, LDL-C testing, and retinal eye exam decreased from 72.7%, 79.6%, and
57.9% before cancer diagnosis to 58.3%, 69.5%, and 55.8% after diagnosis. The pre- and post-diagnosis diabetes
management care was not significantly different by hospital characteristics in the bivariate analysis except for that
the distance between residence and hospital was negatively related to retinal eye exam after diagnosis (P<0.05). The
multivariate analysis did not identify any significant differences in diabetes management care after cancer diagnosis
by hospital characteristics.

Conclusions: Cancer patients received fewer diabetes management care after diagnosis than prior to diagnosis,
even for those who were treated in large comprehensive centers. This may reflect a missed opportunity to connect
diabetic cancer patients to diabetes care. This study provides benchmarks to measure improvements in comorbidity
management among cancer patients.
Keywords: Cancer; care coordination; comorbidity
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Introduction
Because of advances in early detection and treatment
methods, the overall cancer death rate has steadily
declined since the early 1990s and the 5-year survival rate
is now 68%, up from 49% in the 1970s (1). In 2013, the
cancer survivor population in the US was estimated to be
14 million, and a great number of them have comorbid
conditions. Comorbid conditions such as diabetes are major
threats to life for breast and colorectal cancer survivors (2,3).
If diabetes is not well controlled, it can lead to stroke, heart
disease, and disabilities, such as vision problems, kidney
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failure, or amputations of the foot or leg. A systematic
review found that breast and colorectal cancer patients
with diabetes also had worse clinical outcomes than those
without diabetes (2). In addition, pre-existing diabetes is
more prevalent in individuals with breast and colorectal
cancer than other Americans (4,5).
There is well-founded concern that cancer-related
services may compete with ongoing delivery of primary
health care services, such as diabetes care, as patients with
cancer often undergo treatment that includes multiple
services over weeks or months delivered by medical
specialties (6). This care pattern may disrupt usual care
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by overriding health concerns or from specialists “taking
over” responsibility for a patient’s health care while cancer
is being managed. However, it can also be postulated that
since cancer patients have more interactions with the
healthcare system after cancer diagnosis than pre-diagnosis,
they would have additional opportunities to receive
recommended diabetic management services (6-8). A recent
study found that diabetic cancer patients received similar
diabetic care relative to diabetic patients without cancer
in a health maintenance organization (6). Another study
found that survivors with diabetes enrolled in traditional
fee-for-service Medicare were significantly less likely than
diabetic patients without cancer to have regular diabetes
examinations (7). These results potentially indicate that the
health care delivery model may play a role in coordinating
diabetes care.
This study examined the influence of cancer care delivery,
such as characteristics of the hospital where the patient was
treated, and the patient’s overall reliance on that hospital
for their cancer on diabetes care among cancer patients
with Medicare insurance. We expected that physicians at
different hospitals would have different levels of motivation
and capacity to recommend management services to cancer
patients with diabetes, which could produce heterogeneity
in diabetes care among survivors. In the present study, we
compared the quality of diabetes management delivered
to diabetic patients who had cancer surgery in small
hospitals and patients treated in large cancer centers, and
considered the effects of care fragmentation and distance on
the outcome. The present study provides new insights by
using a population-based sample of Medicare beneficiaries
diagnosed with breast or colorectal cancer to examine the
effect of several characteristics of the hospital where the
patient was treated on measures of diabetes management
quality outcomes before and after diagnosis.
Methods
Data and study cohort
This study is a part of a large project to study the pattern
and quality of cancer care in breast and colorectal cancer
patients living in Appalachian counties in North Carolina,
Ohio, Kentucky, and Pennsylvania (9,10). This project
obtained state central cancer registry data on breast and
colorectal cancer incidence for 2006-2008. Patient data
were linked to Medicare enrollment files using patients’
social security numbers, first and last names, gender, and
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dates of birth. These data are likely to have complete claims
during 2005-2009 for patients not enrolled in a health
maintenance organization. Data that were similarly linked
have been used extensively in cancer care research (11-14).
Patients age 21 or older diagnosed with a first primary
breast or colorectal cancer in 2006-2008 were identified
in the linked data. The cancer registry data recorded the
sequence number of reported tumors of each patient. We
included those enrolled 1 year before and 1 year after
diagnosis in both Medicare parts A (hospital insurance) and
B (medical insurance). Cases with enrollment in Medicare
Advantage or HMO involvement during the 2-year time
frame were excluded. Cases with prior cancer diagnosis
were excluded. Autopsy cases and cases where death was
recorded within 1 year from diagnosis were excluded. Of
these, 2,907 patients were diagnosed with diabetes 1 year
before their cancer diagnosis and received surgery 6 months
after cancer diagnosis. We then identified the facility where
colorectal cancer surgery was conducted using the reporting
hospital fields from the cancer registries data together with
the “class of case” variable indicating if the reporting facility
was the treatment facility. In addition we supplemented
this identification by searching for treatment facility using
Medicare claims files (Table S1). This resulted in 2,707
patients in the final sample (Figure 1).
Diabetes management services
We assessed three measures of diabetes technical quality
and clinical outcomes based on definitions proposed by the
Diabetes Quality Improvement Program (DQIP) and 2004
Health Plan Employer Data and Information Set (HEDIS):
glycated hemoglobin (HbAlc) testing every 6 months,
serum cholesterol level (LDL-C) testing every year, and
dilated retinal eye exam every year (15,16). For example,
healthcare systems, such as Partners HealthCare, also use
these three measures to develop their report cards (17).
HbA1c is a lab test that shows the average level of blood
sugar (glucose) and registry cancer diagnosis variables
(Table S1).
Explanatory variables
The main explanatory variables of concordance concerned
characteristics of the hospital where surgery was completed.
Most patients completed their adjuvant therapy in the
hospital or cancer center where surgery was completed
or the outpatient clinics of these hospitals. We calculated
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Colorectal and female breast cancers with diagnostic
confirmation, excluding autopsies (n=50,202)

Limited to cases with 1 year Part A&B enrollment
pre/post diagnosis in Medicare (n=22,341)

Excluded cases enrolled in an HMO or Medicare
Advantage Program and those with mismatching
gender and birthdates between registry and
Medicare sources (n=14,166)

Limited to tumors reported
first per patient (n=10,819)

Surviving at least 1 year after diagnosis (n=10,775)

Limited to cases that were diagnosed with diabetes
1 year before their cancer diagnosis and received
surgery in six months after cancer diagnosis
(n=2,907)

Limited to cases that are reported by the
colorectal cancer surgery hospital (n=2,707)

Figure 1 Patient selection criteria.

volume of care variables based on all 2008 national
Medicare claims associated with the hospitals in our
database. All claims with procedure codes for breast and
colorectal cancer surgical codes were singled out, and all
non-duplicate unique claims for the hospital were summed.
Surgery volume quartiles calculated over the sample were
assigned to patients depending on the type of cancer (e.g.,
colorectal cancer resection volume quartiles for patients
with colorectal cancer diagnosis). A volume of diabetes care
variable was calculated using all available 2008 Medicare
claims associated with facilities surrounding the study
region, including claims not associated with patients
within the sample. For each facility, all claims during 2008
associated with a diabetes ICD-9 diagnosis initiating with
“250” were selected, duplicates were removed, and the
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number of unduplicated claims was then summed to arrive
at a volume variable.
Number of beds, ownership information, and service mix
(the number of high tech services such as acute renal dialysis,
burn care unit, organ transplant) were obtained from the
Provider of Service (POS) file available from the Centers for
Medicare and Medicaid Services (CMS) particular to the year
2007. Commission on Cancer (CoC) accreditation status
was obtained by consulting accreditation history (particular
to 2007) from the web site facility locator (18). The ratio
of total Medicaid inpatient days to total inpatient days
was extracted from Healthcare Cost Report Information
(HCRIS) data (19). We used the 2010 American Hospital
Association survey data to extract information of the
organizational structure of the hospital (centralized,
centralized physician/insurance, decentralized, freestanding,
independent, and moderately centralized). Patients’
residential distance from the surgical site was calculated as
driving distance from the listed patient residential address
to the surgical facility location. The addresses of both
the patients and facilities were obtained from the Cancer
Registry patient data and Medicare Provider of Service file.
Driving distances between the addresses were geocoded
and calculated with ArcGIS using the ESRI Street Map Pro
network file.
Patient level variables were extracted from the cancer
registry data and included age at diagnosis, gender, race/
ethnic status, derived America Join Committee on Cancer
(AJCC) stage grouping, tumor size, cancer site, surgery,
and state of residence. A two-level diabetes severity score
was calculated. Patients with low risk diabetes did not
have complications or use insulin. Patients on insulin
and patients with diabetes complications and diabetic
ketoacidosis hospital episodes were classified as intermediate
to high risk. A comorbidity score was calculated using the
ACE-27 measure (excluding diabetes from the metric) as it
captures more comorbidities than the Charlson comorbidity
index (20). The four-level overall score ranges from 0 (no
comorbidity burden) to 3 (severe comorbidity burden). In
addition, patients were also classified by whether or not
they received surgery at the facility where their cancer was
diagnosed. (Patient’s pattern of use of facilities for cancer
care were determined from NAACCR coding on ‘class
of case’ reported for the surgical facility, and from CMS
POS data where place of service was identified. Patients
were initially defined as have ‘sole source’ cancer care
if they were coded as class of case “1” (Diagnosis at the
accessioning facility, and all or part of the first course of
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treatment was performed). CMS claims data were used to
reclassify patients with class of case =1 as having fragmented
care if they received chemotherapy services from a location
other than the surgical facility site.) County level contextual
variables where assigned to each patient based on residence
at time of diagnosis. Data of contextual variables were
drawn from the American Community Survey, Area
Resource Files, and Appalachian Regional Commission
(21-23). Important variables of socioeconomic status, such
as family income and educational level, were not accessible
due to data limitations.
Multivariate analysis
Association of post-diagnosis concordance measures with
facility characteristics was examined using bivariate and
multivariate analysis, in all cases adjusting for pre-diagnosis
measures. For bivariate analysis, significance tests were
conducted using logistic regression with post-diagnosis
concordance as the dependent variable and examining the
Wald test P values testing the bivariate association. For the
multivariate analysis, all facility variables were included
as independent variables in the model and the association
with each variable was tested using Wald tests P values.
In addition to previous concordance measures, selected
demographics, tumor factors, and county level factors were
included in the regression model using sequential forward
regression and choosing the best fit regression model with
the smallest Akaike Information Criteria.
Trend analysis
The follow-up period in the multivariate analyses was
relatively short but used a relatively large sample size. In
order to examine the pattern of diabetes management care
over a relatively long time, we used only those patients
who were continually enrolled in traditional Medicare
for 3 years to conduct the trend analysis (N=1,665). A
generalized estimating equations (GEE) main effect
regression was conducted. Independent variables in the
model included corresponding management care prior to
diagnosis, time period (treated as a categorical variable), age
groups, gender, race, comorbidity, diabetes severity, stage
at diagnosis, tumor size, and type of surgery. Observations
were clustered by patient and the unstructured covariance
was chosen. Further, observations with missing data in the
covariates were excluded. Expected probabilities of care
were calculated by evaluating probabilities predicted by
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the model at the mean values for continuous variables and
balanced rates for categorical variables.
Results
Table 1 shows that the median age of our sample was
74.4 years old. Our sample contained proportionately more
female patients (76.5%). Both breast and colorectal cancer
patients were predominately white (95.5%). Most patients
(78.7%) were diagnosed with tumors smaller than 5 cm in
size with early stage diseases (78.7%). Comorbidity burden
among these patients was substantial: 90.5% of cancer
patients had at least some level of burden, and nearly 19%
had ‘severe’ comorbidity burden, which is associated with
decreased survival after surgery. Almost 42% of these cancer
patients had severe diabetes.
The overall rates of HbAlc testing, LDL-C testing,
and retinal eye examinations before cancer diagnosis were
72.7%, 79.6%, and 57.9%, respectively (Table 2). The
rates of HbAlc testing, LDL-C testing, and retinal eye
examinations decreased after cancer diagnosis (58.3%,
P<0.001; 69.5%, P<0.001; and 55.8%, P<0.05 respectively).
In addition, there were no significant differences in
guideline-concordant diabetes care before or after cancer
diagnosis by characteristics of the hospital where the patient
was treated such as CoC designation, number of beds,
ownership, the ratio of Medicaid inpatient days, surgery
volume, diabetes service volume, medical service mix, and
organizational structure. We only found that the distance
between the patient’s residence and hospital was negatively
related to retinal eye testing (P value =0.0242).
When patient and tumor characteristics were controlled,
the strongest predictor of receiving diabetes care after
cancer diagnosis was if the patient had received the same
service before cancer diagnosis, which is consistent across
three outcome measures (Table 3). For example, patients
who received LDL-C testing before cancer diagnosis had
five times the odds of having an LDL-C testing after cancer
diagnosis when compared to those who didn’t receive an
LDL-C testing before cancer diagnosis. There weren’t any
significant differences in HbAlc testing, LDL-C testing,
and retinal eye exam care before or after cancer diagnosis by
hospital characteristics.
The trend analyses (Table 4) showed that the predicted
probability of HbAlc testing, LDL-C testing, and retinal
eye examinations decreased the first year after cancer
diagnosis but then increased in the second year after
diagnosis. For example, the predicted probability of
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Table 1 Demographic and tumor characteristics and county-level

Table 1 (continued)

factors (n=2,707)

Characteristics

Characteristics

N (%)

Gender
Female
Male

2,072 (76.54)
635 (23.46)

Race/ethnicity
White non-hispanic
Other

N (%)

Surgery type
Breast conserving surgery

838 (30.96)

Colorectal cancer surgery

1,291 (47.69)

Mastectomy

578 (21.35)

County economic status
2,585 (95.50)

Competitive

122 (4.51)

Transitional

Comorbidity (non-diabetes)

461 (17.03)
1,719 (63.50)

At risk

296 (10.93)

Distressed

231 (8.53)

0

256 (9.46)

I

1,309 (48.36)

II

617 (22.79)

(weighted mean ) (%)

III

525 (19.39)

White not hispanic (weighted meanǂ) (%)

87.95

Population with high school diploma
ǂ

ǂ

Population in poverty (weighted mean ) (%)

Diabetes severity
Low risk

1,574 (58.15)

No. of general practice practitioners per

Intermediate to high risk

1,133 (41.85)

100,000 people (weighted meanǂ)
ǂ

State of residence
Kentucky

350 (12.93)

North Carolina

379 (14.00)

Ohio

568 (20.98)

Pennsylvania

1,410 (52.09)

Metropolitan status
Metro

1,367 (50.50)

Non-metro

1,340 (49.50)

AJCC stage at diagnosis
Stage 0

349 (13.37)

Stage I

892 (34.16)

Stage II

815 (31.21)

Stage III

441 (16.89)

Stage IV

114 (4.37)

Tumor size (cm)
<0.5

76 (3.27)

0.5-1

217 (9.35)

1-2

580 (24.98)

2-3

429 (18.48)

3-4

288 (12.40)

4-5

237 (10.21)

>5

495 (21.32)

Primary site
Breast

1,416 (52.31)

Colon

1,052 (38.86)

Rectosigmoid
Rectum

80 (2.96)
159 (5.87)

Table 1 (continued)
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86.69
13.33
242.14

, weighted by the 2,000 census population number. AJCC,

American Joint Committee on Cancer.

HbA1c testing decreased from 0.73 before diagnosis to
0.57 at the first 6 months after diagnosis, and gradually
increased in the next year and a half (0.64, 0.66, 0.67,
P<0.0001). The other two measures followed a similar
trend pattern as that for HbAlc testing, but did not reach
statistical significance (P=0.0002 for LDL-C testing and
P=0.0694 for retinal eye exam).
Discussion
This study provides population-based estimates of diabetes
management care before and after cancer diagnosis.
Although scientific attention to diabetes care among
cancer patients is increasing (2,6-8), this is the first study to
compare diabetes management care before and after cancer
diagnosis and examine if diabetes management care among
cancer patients was associated with the characteristics
of the hospital where cancer surgery was performed.
We found that cancer patients received fewer diabetes
management services after diagnosis than prior to diagnosis.
The predicted probability of diabetes management tests
decreased at first after diagnosis and gradually increased
thereafter. It does not appear that there is a particular
advantage to being treated for cancer in a larger or CoC
designated hospital or those with higher surgical volumes,
at least in terms of concordance with diabetes guidelines.
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Table 2 Concordance rates of diabetes management care by characteristics of the hospital where the patient was treated
Characteristics

N (%)

HBA1c

LDL-C

Retinal eye

Pre (%)

Post (%)

Pre (%)

Post (%)

Pre (%)

Post (%)

2,707

72.70

58.26

79.60

69.49

57.90

55.82

1,723 (63.65)

73.13

57.37

79.22

69.94

58.56

57.11

984 (36.35)

71.95

59.86

80.18

68.70

56.71

53.56

327 (12.08)

74.62

63.61

79.51

70.03

57.49

55.96

100-199

562 (20.76)

74.38

59.96

80.78

70.28

57.12

55.34

200-499

1,279 (47.25)

71.23

55.98

79.91

68.88

57.54

54.65

539 (19.91)

73.28

58.63

77.55

69.76

59.74

59.00

128 (4.73)

75.00

55.47

84.38

73.44

57.81

52.34

Government

193 (7.13)

72.02

59.59

79.27

68.91

55.96

51.81

Not for profit

2,386 (88.14)

72.63

58.30

79.34

69.32

58.05

56.33

Total
CoC Designation
CoC
Non-CoC
No. of beds
<100

>500
Facility type
For profit

Medicaid inpatient days ratio
<10%

1,498 (55.61)

71.36

56.61

78.70

68.69

58.68

57.48

10-20%

883 (32.78)

74.86

61.38

81.09

69.54

58.10

55.15

>20%

313 (11.62)

72.84

57.51

79.87

73.48

53.67

50.48

1st quartile (0-13 CRC, 0-23 BC)

644 (23.79)

73.60

60.71

78.11

66.61

55.90

55.59

2nd quartile (14-24 CRC, 24-42 BC)

726 (26.82)

71.07

56.06

78.93

70.39

57.85

53.58

3rd quartile (25-42 CRC, 43-63 BC)

678 (25.05)

74.19

58.11

81.71

70.50

57.23

56.05

4th quartile (43+ CRC, 64+ BC)

659 (24.34)

72.08

58.42

79.51

70.26

60.55

58.27

1st quartile (0-4.6 mi)

704 (26.01)

73.15

59.38

78.55

69.89

62.22

59.66

2nd quartile (4.6-10.4 mi)

694 (25.64)

69.60

58.65

75.36

65.56

56.63

57.35

3rd quartile (10.4-22.3 mi)

682 (25.19)

73.02

57.33

81.96

70.38

59.82

56.60

4th quartile (>22.4 mi)

627 (23.16)

75.28

57.58

82.78

72.41

52.31

48.96

1st quartile [0-150]

662 (24.46)

74.47

60.73

81.72

68.88

58.01

54.83

2nd quartile [150-310]

661 (24.43)

73.68

59.76

80.03

69.74

54.16

53.10

3rd quartile [310-180]

742 (27.42)

72.64

57.55

78.17

67.92

61.05

57.95

4th quartile [>581]

641 (23.69)

70.05

54.91

78.47

71.76

57.88

57.25

1st quartile [0-6]

613 (22.64)

75.53

61.50

80.91

69.98

57.79

54.65

2nd quartile [7-8]

800 (29.55)

71.13

56.75

77.88

69.00

54.75

53.50

3rd quartile [9-10]

534 (19.73)

70.79

56.93

78.09

65.54

58.61

58.05

4th quartile [11-18]

760 (28.08)

73.42

58.16

81.32

72.37

60.92

57.63

Centralized health system

134 (4.95)

72.39

60.45

82.84

72.39

60.45

59.70

Centralized physician/insurance health system

281 (10.38)

75.44

58.36

77.22

71.17

61.57

61.92

Decentralized health system

382 (14.11)

68.59

55.50

79.06

69.63

53.93

50.79

Freestanding hospital system

1,113 (41.12)

74.03

58.40

79.87

69.63

56.24

54.63

Independent hospital system

120 (4.43)

65.83

53.33

79.17

64.17

64.17

55.83

Moderately centralized health system

677 (25.01)

72.97

59.97

79.76

68.83

59.68

57.31

Surgery volume

Distance to facility*

Diabetes service volume [No. of claims]

No. of high tech medical services

Health system

*P=0.0242 for retinal eye exam. P values are based on Wald contrasts from logistic regression adjusting examining overall association after adjusting for
previous value before diagnosis. Only showing the P values that are smaller than 0.05. CoC, Commission on Cancer.
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Table 3 Odds ratios (95% CI) of receiving diabetes management care after cancer diagnosis
Characters
Pre-diagnosis
COC designation

HBA1c

LDL-C

4.85 (4.00-5.88)
P=0.6429

5.10 (4.13-6.30)
P=0.5592

COC

1.17 (0.92-1.50)

0.93 (0.71-1.20)

Non-COC

1.00 (reference)

1.00 (reference)

No. of beds

P=0.7653

P=0.2369

Retinal eye
4.83 (4.06-5.74)
P=0.2650
1.15 (0.90-1.47)
1.00 (reference)
P=0.4343

<100

1.04 (0.64-1.69)

1.06 (0.63-1.77)

1.11 (0.69-1.81)

100-199

1.00 (0.69-1.45)

0.88 (0.59-1.32)

1.16 (0.80-1.68)

200-499

0.90 (0.68-1.20)

0.79 (0.58-1.08)

0.93 (0.70-1.23)

>500

1.00 (reference)

1.00 (reference)

Facility type

P=0.7777

P=0.4348

1.00 (reference)
P=0.8227

For profit

0.85 (0.54-1.35)

1.06 (0.64-1.75)

0.91 (0.58-1.43)

Government

1.03 (0.70-1.52)

1.31 (0.87-1.98)

0.90 (0.62-1.33)

Not for profit
Medicaid bed days ratio

1.00 (reference)

1.00 (reference)

P=0.0669

P=0.1666

1.00 (reference)
P=0.8526

<10%

1.02 (0.72-1.46)

0.69 (0.47-1.02)

1.09 (0.79-1.50)

10-20%

1.29 (0.91-1.83)

0.72 (0.49-1.05)

1.06 (0.76-1.47)

>20%

1.00 (reference)

1.00 (reference)

1.00 (reference)

Surgery volume

P=0.7548

P=0.5239

P=0.2559

Low volume quartile

0.89 (0.62-1.29)

0.99 (0.67-1.46)

2nd quartile

0.86 (0.64-1.14)

1.18 (0.87-1.61)

0.82 (0.61-1.09)

3rd quartile

0.90 (0.69-1.17)

1.13 (0.86-1.50)

1.00 (0.77-1.30)

High volume quartile

1.00 (reference)

1.00 (reference)

1.00 (reference)

Distance to facility

P=0.2086

P=0.3735

1.03 (0.72-1.48)

P=0.4245

Low 1st quartile (0-4.6 mi)

1.28 (0.97-1.70)

1.03 (0.77-1.38)

2nd quartile (4.6-10.4 mi)

1.31 (0.99-1.73)

0.83 (0.62-1.11)

1.20 (0.91-1.58)

3rd quartile (10.4-22.3 mi)

1.11 (0.85-1.46)

0.93 (0.70-1.24)

1.18 (0.90-1.54)

High 4th quartile (>22.4 mi)
Diabetes service volume [No. of claims]

1.00 (reference)

1.00 (reference)

P=0.5449

P=0.3397

1.26 (0.95-1.67)

1.00 (reference)
P=0.8921

1st quartile [0-150]

1.18 (0.88-1.58)

0.79 (0.58-1.08)

2nd quartile [150-310]

1.23 (0.92-1.63)

0.93 (0.69-1.25)

0.94 (0.71-1.23)

3rd quartile [310-180]

1.09 (0.85-1.41)

0.82 (0.62-1.08)

0.97 (0.75-1.26)

4th quartile [>581]
No. of high tech services

1.00 (reference)

1.00 (reference)

P=0.8155

P=0.1591

0.89 (0.67-1.19)

1.00 (reference)
P=0.8356

1st quartile [0-6]

1.03 (0.80-1.34)

0.98 (0.74-1.30)

2nd quartile [7-8]

1.01 (0.79-1.29)

0.96 (0.74-1.25)

0.99 (0.78-1.26)

3rd quartile [9-10]

0.90 (0.68-1.19)

0.73 (0.55-0.98)

1.09 (0.83-1.44)

4th quartile [11-18]
Health system

1.00 (reference)

1.00 (reference)

P=0.9342

P=0.7520

0.95 (0.73-1.23)

1.00 (reference)
P=0.4975

Centralized health system

1.11 (0.70-1.75)

0.89 (0.55-1.45)

1.19 (0.76-1.87)

Centr. phys/ins. health system

0.98 (0.70-1.37)

1.23 (0.86-1.77)

1.13 (0.80-1.58)

Decentralized health system

0.90 (0.66-1.24)

1.09 (0.79-1.52)

0.81 (0.60-1.10)

Freestanding hospital system

0.93 (0.72-1.19)

1.00 (0.77-1.31)

0.95 (0.74-1.22)

Independent hospital system

1.05 (0.65-1.71)

0.85 (0.52-1.39)

0.96 (0.60-1.53)

Moderately centralized health system

1.00 (reference)

1.00 (reference)

1.00 (reference)

Patient characteristics, tumor characteristics, and county-level factors were controlled in the regression; HBA1c model included diabetes severity, cancer
stage, rural/urban continuum, ARC economic class, and county of residence poverty rate; LDL1c model included cancer stage, age group, county of
residence poverty rate, and gender; retinal eye model included age, cancer stage, and rural/urban continuum; CoC, Commission on Cancer.

© Annals of Translational Medicine. All rights reserved.

www.atmjournal.org

Ann Transl Med 2015;3(5):72

Yao et al. Diabetes care before and after cancer diagnosis

Page 8 of 10

Table 4 Predicted probabilities of receiving diabetes
management care before and after cancer diagnosis (n=1,665)
Variables

Predicted
probabilities

HBA1c

P<0.0001

6 months before cancer diagnosis

0.73

6 months after cancer diagnosis

0.57

Months 7-12 after cancer diagnosis

0.64

Months 13-18 after cancer diagnosis

0.66

Months 19-24 after cancer diagnosis
LDL-C

0.67
P=0.0002

1 year before cancer diagnosis

0.80

1 year after cancer diagnosis

0.67

2 years after cancer diagnosis
Retinal eye

0.73
P=0.0694

1 year before cancer diagnosis

0.58

1 year after cancer diagnosis

0.55

2 years after cancer diagnosis

0.58

Expected probabilities of care were calculated by
evaluating probabilities predicted by model at the mean
values for continuous variables and balanced rates for
categorical variables.

Although we were not able to measure care coordination,
the results may suggest that the coordination of care for
cancer patients with diabetes is neither better nor worse
for cancer patients treated in the more comprehensive
cancer treatment hospitals. The overall quality of diabetes
care after cancer diagnosis was not associated with hospital
ownership, volume, the number of beds, accreditation,
safety-net burden, travel distance, diabetes service volume,
mix of medical care service, or organizational structure.
This may indicate that hospitals where cancer surgery was
performed were equally poor in coordinating diabetes care
with cancer treatment.
There may be several explanations for the decrease in
diabetes management care quality after cancer diagnosis.
Cancer patients and their physicians may devote more
attention to interventions directly linked to cancerspecific mortality reduction as patients may think cancer
is their greatest threat to life (8). So, primary care might
be deterred by their intensive cancer treatment. From
a provider perspective, cancer care physicians were not
trained to coordinate care for non-cancer related health
concerns, and the cancer care guidelines did not mention

© Annals of Translational Medicine. All rights reserved.

diabetes care (7,24,25). In addition, the Medicare program
did not provide financial incentives to health professionals
to coordinate non-cancer related healthcare. Although large
comprehensive cancer centers were often affiliated with
medical centers with enormous healthcare resources, they
may fail to connect diabetic cancer patients to diabetes care.
Additionally, very few comprehensive cancer centers in the
US have a diabetes program to help cancer patients cope
with their pre-existing diabetes (26).
The Patient Protection and Affordable Care Act (PPACA)
provides a few opportunities for improving non-cancer
related care coordination. The PPACA authorizes grants
to support community-based collaborative care networks
that must be consortiums of health care providers with a
joint governance structure that provides comprehensive
coordinated and integrated health care services. The
Department of Health and Human Services will provide
grants to create community health teams and medical
homes that include an interdisciplinary team of health care
providers which would provide integrated community-based
care for their patients. These policy changes may help small
cancer hospitals coordinate with primary care physicians
in providing diabetes management care to cancer patients.
It does less to ensure the coordination of care if a patient
receives cancer treatment in a comprehensive cancer center.
Our study has both strengths and weaknesses. The first
strength is that we were able to describe diabetes care
before and after cancer diagnosis in the same cohort of
patients. Second, the quality of diabetes care before cancer
diagnosis was very similar among different patient groups
by hospital characteristics in this study. So, patients were
probably not selected on the basis of their diabetes care
before diagnosis. There are also several limitations. We
can only apply these results to elderly cancer patients in
a fee-for-service environment. Although we focused on
elderly cancer patients from four states by design, some
characteristics of healthcare in these four states are shared
by other regions of the US. Thus, the importance of our
findings certainly reaches beyond these four states. The
follow-up time is short in this study, so we were not able
to examine long-term diabetes management care quality
among cancer survivors. We plan to request additional
data to examine if the diabetes care quality improves in the
second or third year after cancer diagnosis. Some cancer
patients may have received adjuvant therapies outside the
hospital where surgery was completed. Our model did not
capture the influence of outpatient clinics which are not
affiliated with the hospital where surgery was conducted.
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Our analysis relies on the accuracy of claims data and the
cancer registry files. There can be mistakes in the billing
data and registry files, but Medicare data are a reliable and
efficient source of data to study medical care among elderly
cancer patients (9,27), and cancer registries are among the
best source of cancer case identification for population
research (12,28,29).
In conclusion, diabetes management care for cancer
patients declined after diagnosis, regardless of where
they received their cancer surgery. This reflects a
missed opportunity to connect diabetic cancer patients
to diabetes care, particularly among patients treated in
large comprehensive cancer centers. This study provides
benchmarks against which to measure improvements in
comorbidity management among cancer patients.
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Supplementary

Table S1 ICD-9 and CPT codes used to define medical services in linked database
Database
Breast conserving

Registry site-specific codes
10-90

ICD-9/nDC medicare
BCS: 85.20-23, 85.25

HCPCS/CPT medicare
BCS: 19120, 19125, 19126, 19160, 19162,
19301, 19302

surgery (BCS) &
mastectomy

Mastectomy: 85.33-36,

Mastectomy: 19180, 19182, 19200, 19220,

85.41-48

19240, 19303, 19304, 19305, 19306, 19307,
19340, 19342

Colorectal surgery/
sampling & removal

10-90

Removal: 45.25-45.27,

Non-oncological sampling and removal: 44025,

45.41-45.43, 45.49,

45355, 44110, 44389, 44392, 44393, 44394,

48.24-48.26, 48.31-48.36,

45378, 45380, 45384, 45385, 45392, 45383

48.8x
Resection: 45.71-76,

Resection: 44140, 44141, 44143, 44144,

45.79, 45.8×, 48.69,

44145, 44146, 44147, 44160, 44204, 44025,

48.41, 48.49, 48.5×,

44206, 44207, 44208, 45110, 45111, 45112,

48.6×, 48.61-65, 45.8×,

45113, 45114, 45116, 45119, 45120, 45121,

46.01-24, 48.5×, 46.50-52

45123, 45126, 44150, 44151, 44152, 44153,
44155, 44156, 44210, 44211, 44212, 44310,
44316, 44300, 44320, 44322, 44605, 45136,
45563, 50810, 44620, 44625, 44626

HbAlc testing

83036, 83037, 3044F, 3045F, 3046F, 3047F

LDL-C test

80061, 83700, 83701, 83704, 83721, 3048F,
3049F, 3050F

Dilated retinal eye exam

14.1×, 14.2×, 14.3×,

67028, 67030, 67031, 67036, 67038, 67039,

14.4×, 14.5×, 14.9×,

67040, 67041, 67042, 67043, 67101, 67105,

95.02-04, 95.11-12,

67107, 67108 67110 67112, 67113, 67121,

95.16; diagnosis: V720

67141, 67145, 67208, 67210, 67218, 67220,
67221 67227, 67228, 92002, 92004, 92012,
92014, 92018, 92019, 92225, 92226, 92230,
92235, 92240, 92250, 92260

